Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.
Researchers found that the use of glucagon-like peptide-1 agonists, known as GLP-1 mimetics, resulted in a systolic blood pressure (SBP) reduction of -2.22 mmHg, a loss of almost six pounds, and a decrease of HbA1c -- an indicator of blood sugar levels -- of 0.41 percent.
http://www.sciencedaily.com/releases/2013/05/130517085058.htm
Researchers found that the use of glucagon-like peptide-1 agonists, known as GLP-1 mimetics, resulted in a systolic blood pressure (SBP) reduction of -2.22 mmHg, a loss of almost six pounds, and a decrease of HbA1c -- an indicator of blood sugar levels -- of 0.41 percent.
http://www.sciencedaily.com/releases/2013/05/130517085058.htm